Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 10, 2007

GTC Biotherapeutics Obtains License to Nuclear Transfer Patents

  • GTC Biotherapeutics was granted a non-exclusive, worldwide license from Start Licensing, a joint venture between Geron and Exeter Life Sciences, for the patents and patent applications developed by the Roslin Institute to apply nuclear transfer to the production of therapeutic proteins in the milk of transgenic animals. 

    Financial terms include an upfront payment of $200,000 to Start and a total of 278,370 shares of GTC common stock, based on the 10-day average closing price ending April 5, divided equally between Start and Exeter. There will also be a royalty payable to Start for those products developed with the patented nuclear transfer technology. The license agreement remains in place through the last patent to expire, which is expected in 2016 for the currently issued patents.

    “We are pleased to enter into this licensing agreement to ensure we have the freedom to operate those programs where the application of nuclear transfer is appropriate for product development,” states Geoffrey F. Cox, Ph.D., GTC’s chairman and CEO. “Our intellectual property portfolio provides patent protection for both the practice of our technology and the commercialization of our products. Last year, we received a patent in the United States for the production of therapeutic proteins in the milk of any transgenic mammal through 2021. This broad and long-lived intellectual property, all of which is independent of traditional bioreactor-based intellectual property, supports our strategic focus on the development and commercialization of recombinant plasma proteins and monoclonal antibodies.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »